Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

European Hemostats Market: Forecast (2017-2023)

Reportlinker
Posted on: 22 Nov 17
European Hemostats Market: Forecast (2017-2023)

PR Newswire

NEW YORK, Nov. 21, 2017

NEW YORK, Nov. 21, 2017 /PRNewswire/ -- Hemostats are instruments used to reduce or halt bleeding during surgery. These can be enabled by the time privileged approaches of smearing pressure, stitching the bleeding or using thermal energy devices.

Read the full report: https://www.reportlinker.com/p05206600

Bleeding control is a significant factor in surgical and trauma settings as it reduces the risk of infection, save operative time and reduces the patient stay in hospitals. As surgical procedures evolve to be more refined and non-invasive, the use of fast acting biologically and synthetically derived hemostats, encompassing fibrin sealants, flow able gelatins and adhesives is becoming increasingly prevalent. Some of the consideration parameters for choosing a particular hemostatic agent include efficiency, type of surgery, patient condition and active bleeding tissue versus pooled blood sites and cost.

European hemostats market is comprehended by type, treatment and end users. Based on type the market is categorized into thrombin based hemostats, gelatin based hemostats, collagen based hemostats, oxidized regenerated cellulose based hemostats, combination hemostats and others.

By treatment the market is further segmented into cardiac surgery, vascular procedures, soft tissue reconstructions, spinal procedures, hepatic resection and others. Based on end users the market is categorized into hospitals, surgery centers, nursing homes and others.

European hemostats market is further analyzed on the basis of countries such as: U.K., Ireland, France, Germany, Spain, Italy, Netherlands, Belgium, Austria, Norway, Sweden, Finland, Denmark, Switzerland, Portugal, Rest of Europe.

Sample Companies profiled in this report are:
B Braun Melsungen AG (Germany),
Gelita Medical GmbH (Germany),
Equimedical (Netherlands),
Pfizer Inc. (U.S.),
Johnson & Johnson Services, Inc. (U.S.),
10+.

Increase in number of surgical procedures will propel the growth of the market. Wide range of applications, continuous advancement in product portfolio, technological advancement facilitating the end users and insurance support to manufacturers in promoting tissue sealants are the major driving forces of European hemostats market.

The research methodology opted for this report incorporates initial segregation of the market by type, treatment, end users and countries. This was followed by mining of market volume and revenue of different type of hemostats employed by various end users with respect to countries are considered.

Bottom up approach was then followed for estimating the global market size and its forecast for period 2017 to 2023. The data figures and supporting insights so collated were validated through primary research process by Key Opinion Leaders (KOLs) which comprised of manufacturers, distributors, suppliers, associations and end users.

Read the full report: https://www.reportlinker.com/p05206600

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

 

View original content:http://www.prnewswire.com/news-releases/european-hemostats-market-forecast-2017-2023-300560747.html

SOURCE Reportlinker

PR Newswire
www.prnewswire.com

Last updated on: 22/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.